Form 4 for ANGO ANGIODYNAMICS INC
Accepted 2023-07-21 00:00:00 ET · period of report 2023-07-19 · accession 0001140361-23-035726 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-21 | 2023-07-19 | ANGO | Trowbridge Stephen A | EVP, CFO | A - Grant | $0.00 | +28.7K | 116.0K | +33% | $0 |
| DM | 2023-07-21 | 2023-07-19 | ANGO | Trowbridge Stephen A | EVP, CFO | A - Grant | $0.00 | +116.8K | 57.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-19 | A | A | 28,691 | $0.00 | 115,979 | D | — | — | (F1) The acquisition of 28,691 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 28,691 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027. |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-07-19 | A | A | 59,378 | $0.00 | 59,378 | D | $8.92 · 2024-07-19 to 2033-07-19 | 59,378 Common Stock | (F3) These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027. |
| 3 | Derivative | Performance Right | 2023-07-19 | A | A | 57,381 | $0.00 | 57,381 | D | — · — to — | 57,381 Common Stock | (F2) Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited. |